You are here: Industry Insights > leukemia

News List

Drug compound could be next-generation treatment for aggressive form of leukemia worldpharmanews
January 30, 2019
Researchers have been struggling for years to find a treatment for patients who have a recurrence of acute myeloid leukemia (AML).
91 percent response rate for venetoclax against newly diagnosed AML in older adults worldpharmanews
November 30, 2018
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML).
Novartis focusing on cutting CAR-T costs ahead of EU launches pharmaphorum
November 26, 2018
Novartis is focusing on cutting manufacturing costs for its CAR-T cancer cell therapy as the company launches it across Europe, while keeping a watching brief on ‘off-the-shelf’ therapies that could potentially be cheaper to produce.
Research claims childhood Leukemia likely to be preventable biospectrumasia
May 23, 2018
Acute lymphoblastic leukemia affects 500 individuals annually in the UK – making it the most common form of cancer in children – and this figure is rising every year.
FDA expands approval of Blincyto for treatment of a type of leukemia in patients who have a certain risk factor for relapse biospace
March 30, 2018
FDA granted accelerated approval to Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukemia (ALL) who are in remission but still have minimal residual disease (MRD)
Novartis drug Tasigna approved by FDA to treat children with rare form of leukemia firstwordpharma
March 23, 2018
Novartis announced today that the FDA expanded the indication for Tasigna® to include treatment of first- and second-line pediatric patients one year of age or older with Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase
Health Canada Approves RITUXAN Subcutaneous Formulation for Canadians with Chronic Lymphocytic Leukemia firstwordpharma
March 23, 2018
Hoffmann-La Roche Limited announced today that Health Canada has approved RITUXAN® subcutaneous for the treatment of patients with previously untreated or previously treated B-cell chronic lymphocytic leukemia, Binet Stage B or C, in combination with flu
Commitment to Curing Cancer: High School Fundraising Campaign Raises $192,000+ in Seven Weeks For Th biospace
March 05, 2018
The Leukemia & Lymphoma Society's(LLS) second annual Students of the Year campaign exceeded all expectations, with 21 Candidate Teams, comprised of 36 extraordinary high school students, raising over $192,000 to help find cancer cures.
Children's Hospital of Philadelphia Release: T Cell Therapy Shows Persistent Benefits in Young Leuke biospace
February 02, 2018
Update on Global Clinical Trial of CAR T Cell Therapy tisagenlecleucel is a landmark personalized treatment of high-risk forms of acute lymphoblastic leukemia (ALL)
Teva Wins FDA Nod for TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promye biospace
January 16, 2018
Teva Announces U.S. FDA Approval of TRISENOX (arsenic trioxide) Injection for First Line Treatment of Acute Promyelocytic Leukemia

Previous page 1 2 3 4 5 Next page